S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths

LeMaitre Vascular Stock Price, News & Analysis (NASDAQ:LMAT)

$54.65
+0.03 (+0.05%)
(As of 12/8/2023 ET)
Compare
Today's Range
$53.90
$54.77
50-Day Range
$45.37
$58.01
52-Week Range
$43.69
$68.67
Volume
168,403 shs
Average Volume
99,440 shs
Market Capitalization
$1.22 billion
P/E Ratio
45.17
Dividend Yield
1.02%
Price Target
$67.60

LeMaitre Vascular MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
23.7% Upside
$67.60 Price Target
Short Interest
Healthy
5.35% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
14.93%
From $1.34 to $1.54 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

133rd out of 932 stocks

Surgical & Medical Instruments Industry

22nd out of 93 stocks


LMAT stock logo

About LeMaitre Vascular Stock (NASDAQ:LMAT)

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access in patients with or without a previously-failed synthetic graft; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

LMAT Stock Price History

LMAT Stock News Headlines

LeMaitre Vascular (NASDAQ:LMAT) Upgraded to Buy by StockNews.com
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
LeMaitre Vascular Inc LMAT
Stifel Nicolaus Reaffirms Their Hold Rating on Lemaitre Vascular (LMAT)
A First Look At LeMaitre Vascular
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Q3 2023 LeMaitre Vascular Inc Earnings Call
LeMaitre Q3 2023 Financial Results
5 Analysts Have This to Say About LeMaitre Vascular
See More Headlines
Receive LMAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Ex-Dividend for 11/30 Dividend
11/15/2023
Dividend Payable
11/30/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LMAT
Employees
591
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$67.60
High Stock Price Target
$75.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+23.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$20.64 million
Pretax Margin
19.38%

Debt

Sales & Book Value

Annual Sales
$161.65 million
Cash Flow
$1.50 per share
Book Value
$12.19 per share

Miscellaneous

Free Float
19,502,000
Market Cap
$1.22 billion
Optionable
Optionable
Beta
0.88

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report














LMAT Stock Analysis - Frequently Asked Questions

Should I buy or sell LeMaitre Vascular stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LMAT shares.
View LMAT analyst ratings
or view top-rated stocks.

What is LeMaitre Vascular's stock price target for 2024?

6 Wall Street analysts have issued 1 year price objectives for LeMaitre Vascular's shares. Their LMAT share price targets range from $60.00 to $75.00. On average, they expect the company's stock price to reach $67.60 in the next year. This suggests a possible upside of 23.7% from the stock's current price.
View analysts price targets for LMAT
or view top-rated stocks among Wall Street analysts.

How have LMAT shares performed in 2023?

LeMaitre Vascular's stock was trading at $46.02 on January 1st, 2023. Since then, LMAT stock has increased by 18.8% and is now trading at $54.65.
View the best growth stocks for 2023 here
.

When is LeMaitre Vascular's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our LMAT earnings forecast
.

How were LeMaitre Vascular's earnings last quarter?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) posted its earnings results on Wednesday, November, 1st. The medical instruments supplier reported $0.33 EPS for the quarter, topping the consensus estimate of $0.31 by $0.02. The medical instruments supplier had revenue of $47.40 million for the quarter, compared to analyst estimates of $47.58 million. LeMaitre Vascular had a net margin of 14.69% and a trailing twelve-month return on equity of 9.83%. LeMaitre Vascular's quarterly revenue was up 21.5% on a year-over-year basis. During the same quarter last year, the business posted $0.25 earnings per share.

How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular?

LeMaitre Vascular declared a quarterly dividend on Tuesday, October 24th. Stockholders of record on Thursday, November 16th will be given a dividend of $0.14 per share on Thursday, November 30th. This represents a $0.56 annualized dividend and a dividend yield of 1.02%. The ex-dividend date is Wednesday, November 15th.
Read our dividend analysis for LMAT
.

Is LeMaitre Vascular a good dividend stock?

LeMaitre Vascular (NASDAQ:LMAT) pays an annual dividend of $0.56 per share and currently has a dividend yield of 1.03%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 46.28%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LMAT will have a dividend payout ratio of 36.36% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LMAT.

What ETFs hold LeMaitre Vascular's stock?

ETFs with the largest weight of LeMaitre Vascular (NASDAQ:LMAT) stock in their portfolio include Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), Invesco S&P SmallCap Health Care ETF (PSCH) and iShares Micro-Cap ETF (IWC).iShares U.S. Medical Devices ETF (IHI).

What guidance has LeMaitre Vascular issued on next quarter's earnings?

LeMaitre Vascular issued an update on its FY23 earnings guidance on Wednesday, November, 1st. The company provided earnings per share guidance of $1.30-1.35 for the period, compared to the consensus EPS estimate of $1.28. The company issued revenue guidance of $192.6-194.6 million, compared to the consensus revenue estimate of $195.01 million.

What is George W. LeMaitre's approval rating as LeMaitre Vascular's CEO?

13 employees have rated LeMaitre Vascular Chief Executive Officer George W. LeMaitre on Glassdoor.com. George W. LeMaitre has an approval rating of 33% among the company's employees. This puts George W. LeMaitre in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of LeMaitre Vascular own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LeMaitre Vascular investors own include AbbVie (ABBV), Sociedad Química y Minera de Chile (SQM), Gilead Sciences (GILD), Aurora Cannabis (ACB), Aurora Cannabis (ACBFF), NVIDIA (NVDA), Adobe (ADBE), Boeing (BA) and Salesforce (CRM).

Who are LeMaitre Vascular's major shareholders?

LeMaitre Vascular's stock is owned by a variety of institutional and retail investors. Top institutional investors include Conestoga Capital Advisors LLC (8.61%), Copeland Capital Management LLC (5.53%), Ranger Investment Management L.P. (4.04%), Congress Asset Management Co. MA (2.28%), Northern Trust Corp (1.37%) and Ameriprise Financial Inc. (1.18%). Insiders that own company stock include Bridget A Ross, David B Roberts, George W Lemaitre, George W Lemaitre, John A Roush, Joseph P Pellegrino Jr, Lawrence J Jasinski and Trent G Kamke.
View institutional ownership trends
.

How do I buy shares of LeMaitre Vascular?

Shares of LMAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does LeMaitre Vascular have any subsidiaries?
The following companies are subsidiares of LeMaitre Vascular: Artegraft, Bio Nova Holdings Pty Ltd, Bio Nova International Pty Ltd, Biomateriali, CardioCel, Clinical Instruments, Credent, Endomed, Ideas for Medicine, Inavein, LeMaitre Acquisition LLC, LeMaitre Cardial SAS, LeMaitre Medical Technology (Shanghai) Co., LeMaitre Vascular, LeMaitre Vascular AS, LeMaitre Vascular GK, LeMaitre Vascular GmbH, LeMaitre Vascular Pty Ltd, LeMaitre Vascular S.r.l., LeMaitre Vascular SAS, LeMaitre Vascular Singapore Pte Ltd, LeMaitre Vascular Spain, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LifeSpan, PeriVu, ProCol, Restore Flow Allografts, RestoreFlow, Syntel and Python, TRIVEX, Tru-Incise (Eze-Sit) OUS, Tru-Incise (Eze-Sit) US, UnBalloon, VCS Clip, VascuCel, Vascular Architects, Vascular Innovations, Vascutech Acquisition LLC, Vermed, Whittaker Screen Printing, XenoSure, and Xenotis Pty Ltd.
Read More
This page (NASDAQ:LMAT) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -